Switch to:
Also traded in: France, Germany, Italy, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.59
SNY's Cash-to-Debt is ranked lower than
67% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.05 vs. SNY: 0.59 )
Ranked among companies with meaningful Cash-to-Debt only.
SNY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.48 Max: 10.62
Current: 0.59
0.14
10.62
Equity-to-Asset 0.57
SNY's Equity-to-Asset is ranked lower than
62% of the 731 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. SNY: 0.57 )
Ranked among companies with meaningful Equity-to-Asset only.
SNY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.58 Max: 0.65
Current: 0.57
0.48
0.65
Debt-to-Equity 0.32
SNY's Debt-to-Equity is ranked lower than
51% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. SNY: 0.32 )
Ranked among companies with meaningful Debt-to-Equity only.
SNY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05  Med: 0.22 Max: 0.39
Current: 0.32
0.05
0.39
Interest Coverage 19.23
SNY's Interest Coverage is ranked lower than
63% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 112.31 vs. SNY: 19.23 )
Ranked among companies with meaningful Interest Coverage only.
SNY' s Interest Coverage Range Over the Past 10 Years
Min: 7.88  Med: 15.4 Max: 19.65
Current: 19.23
7.88
19.65
Piotroski F-Score: 7
Altman Z-Score: 1.95
Beneish M-Score: -2.62
WACC vs ROIC
6.05%
8.22%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 19.34
SNY's Operating Margin % is ranked higher than
79% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.95 vs. SNY: 19.34 )
Ranked among companies with meaningful Operating Margin % only.
SNY' s Operating Margin % Range Over the Past 10 Years
Min: 15.25  Med: 18.36 Max: 20.7
Current: 19.34
15.25
20.7
Net Margin % 25.35
SNY's Net Margin % is ranked higher than
74% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.06 vs. SNY: 25.35 )
Ranked among companies with meaningful Net Margin % only.
SNY' s Net Margin % Range Over the Past 10 Years
Min: 11.88  Med: 13.66 Max: 25.35
Current: 25.35
11.88
25.35
ROE % 16.30
SNY's ROE % is ranked higher than
55% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.91 vs. SNY: 16.30 )
Ranked among companies with meaningful ROE % only.
SNY' s ROE % Range Over the Past 10 Years
Min: 6.5  Med: 8.61 Max: 16.3
Current: 16.3
6.5
16.3
ROA % 9.03
SNY's ROA % is ranked higher than
55% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. SNY: 9.03 )
Ranked among companies with meaningful ROA % only.
SNY' s ROA % Range Over the Past 10 Years
Min: 3.78  Med: 5.11 Max: 9.03
Current: 9.03
3.78
9.03
ROC (Joel Greenblatt) % 53.78
SNY's ROC (Joel Greenblatt) % is ranked higher than
82% of the 793 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.48 vs. SNY: 53.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SNY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 31.14  Med: 42.95 Max: 63.82
Current: 53.78
31.14
63.82
3-Year Revenue Growth Rate 4.70
SNY's 3-Year Revenue Growth Rate is ranked lower than
52% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. SNY: 4.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SNY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -3.5  Med: 6.3 Max: 27.4
Current: 4.7
-3.5
27.4
3-Year EBITDA Growth Rate -1.70
SNY's 3-Year EBITDA Growth Rate is ranked lower than
70% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. SNY: -1.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SNY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -7.1  Med: 4.2 Max: 35.5
Current: -1.7
-7.1
35.5
3-Year EPS without NRI Growth Rate 7.70
SNY's 3-Year EPS without NRI Growth Rate is ranked higher than
50% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. SNY: 7.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SNY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -13.4  Med: 3.4 Max: 41.7
Current: 7.7
-13.4
41.7
GuruFocus has detected 2 Warning Signs with Sanofi SA $SNY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SNY's 30-Y Financials

Financials (Next Earnings Date: 2017-11-02)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

SNY Guru Trades in Q3 2016

NWQ Managers 335,521 sh (New)
Barrow, Hanley, Mewhinney & Strauss 31,320,327 sh (+11.37%)
Dodge & Cox 59,267,298 sh (+7.45%)
John Paulson 417,000 sh (+5.44%)
HOTCHKIS & WILEY 12,041,028 sh (+5.33%)
Sarah Ketterer 394,507 sh (+0.18%)
Warren Buffett 3,905,875 sh (unchged)
David Dreman 20,204 sh (unchged)
Murray Stahl 27,697 sh (unchged)
Francis Chou 410,000 sh (unchged)
Lee Ainslie Sold Out
Charles Brandes 3,557,856 sh (-1.19%)
Manning & Napier Advisors, Inc 284,817 sh (-1.25%)
John Buckingham 120,078 sh (-2.76%)
Joel Greenblatt 32,879 sh (-7.57%)
PRIMECAP Management 2,037,207 sh (-8.16%)
Ken Fisher 12,443,197 sh (-8.76%)
Bill Nygren 3,170,000 sh (-42.05%)
» More
Q4 2016

SNY Guru Trades in Q4 2016

NWQ Managers 483,670 sh (+44.15%)
Dodge & Cox 68,508,540 sh (+15.59%)
Joel Greenblatt 33,032 sh (+0.47%)
Ken Fisher 12,492,035 sh (+0.39%)
Bill Nygren 3,170,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Francis Chou 410,000 sh (unchged)
PRIMECAP Management 2,037,207 sh (unchged)
Murray Stahl 26,697 sh (-3.61%)
Charles Brandes 3,387,715 sh (-4.78%)
HOTCHKIS & WILEY 11,338,645 sh (-5.83%)
Barrow, Hanley, Mewhinney & Strauss 29,377,146 sh (-6.20%)
Sarah Ketterer 352,841 sh (-10.56%)
Manning & Napier Advisors, Inc 226,188 sh (-20.58%)
John Buckingham 93,371 sh (-22.24%)
John Paulson 253,000 sh (-39.33%)
David Dreman 1,030 sh (-94.90%)
» More
Q1 2017

SNY Guru Trades in Q1 2017

John Rogers 17,794 sh (New)
Manning & Napier Advisors, Inc 244,282 sh (+8.00%)
Charles Brandes 3,490,226 sh (+3.03%)
NWQ Managers 497,766 sh (+2.91%)
Ken Fisher 12,615,505 sh (+0.99%)
Barrow, Hanley, Mewhinney & Strauss 29,418,481 sh (+0.14%)
John Buckingham 93,401 sh (+0.03%)
Warren Buffett 3,905,875 sh (unchged)
Murray Stahl 26,697 sh (unchged)
Francis Chou 410,000 sh (unchged)
Bill Nygren Sold Out
David Dreman Sold Out
PRIMECAP Management 2,024,807 sh (-0.61%)
Dodge & Cox 67,977,413 sh (-0.78%)
Joel Greenblatt 32,588 sh (-1.34%)
HOTCHKIS & WILEY 10,364,345 sh (-8.59%)
Sarah Ketterer 305,620 sh (-13.38%)
John Paulson 150,000 sh (-40.71%)
» More
Q2 2017

SNY Guru Trades in Q2 2017

David Dreman 132 sh (New)
Ken Fisher 13,638,458 sh (+8.11%)
John Buckingham 95,974 sh (+2.75%)
Manning & Napier Advisors, Inc 244,412 sh (+0.05%)
Warren Buffett 3,905,875 sh (unchged)
Joel Greenblatt 32,588 sh (unchged)
Francis Chou 410,000 sh (unchged)
John Rogers 17,790 sh (-0.02%)
Charles Brandes 3,455,511 sh (-0.99%)
PRIMECAP Management 1,982,707 sh (-2.08%)
Murray Stahl 25,697 sh (-3.75%)
Dodge & Cox 62,683,955 sh (-7.79%)
Barrow, Hanley, Mewhinney & Strauss 25,306,756 sh (-13.98%)
NWQ Managers 394,104 sh (-20.83%)
HOTCHKIS & WILEY 5,825,348 sh (-43.79%)
John Paulson 52,000 sh (-65.33%)
Sarah Ketterer 97,036 sh (-68.25%)
» More
» Details

Insider Trades

Latest Guru Trades with SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2017-06-30 Reduce -7.79%0.2%$44.09 - $50.21 $ 49.083%62,683,955
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Reduce -13.98%0.28%$44.09 - $50.21 $ 49.083%25,306,756
Ken Fisher 2017-06-30 Add 8.11%0.08%$44.09 - $50.21 $ 49.083%13,638,458
HOTCHKIS & WILEY 2017-06-30 Reduce -43.79%0.81%$44.09 - $50.21 $ 49.083%5,825,348
Charles Brandes 2017-06-30 Reduce -0.99%0.02%$44.09 - $50.21 $ 49.083%3,455,511
NWQ Managers 2017-06-30 Reduce -20.83%0.06%$44.09 - $50.21 $ 49.083%394,104
John Paulson 2017-06-30 Reduce -65.33%0.06%$44.09 - $50.21 $ 49.083%52,000
John Rogers 2017-06-30 Reduce -0.02%$44.09 - $50.21 $ 49.083%17,790
David Dreman 2017-06-30 New Buy$44.09 - $50.21 $ 49.083%132
Dodge & Cox 2017-03-31 Reduce -0.78%0.02%$39.51 - $45.38 $ 49.0816%67,977,413
Barrow, Hanley, Mewhinney & Strauss 2017-03-31 Add 0.14%$39.51 - $45.38 $ 49.0816%29,418,481
Ken Fisher 2017-03-31 Add 0.99%0.01%$39.51 - $45.38 $ 49.0816%12,615,505
HOTCHKIS & WILEY 2017-03-31 Reduce -8.59%0.16%$39.51 - $45.38 $ 49.0816%10,364,345
Charles Brandes 2017-03-31 Add 3.03%0.07%$39.51 - $45.38 $ 49.0816%3,490,226
NWQ Managers 2017-03-31 Add 2.91%0.01%$39.51 - $45.38 $ 49.0816%497,766
John Paulson 2017-03-31 Reduce -40.71%0.05%$39.51 - $45.38 $ 49.0816%150,000
Joel Greenblatt 2017-03-31 Reduce -1.34%$39.51 - $45.38 $ 49.0816%32,588
John Rogers 2017-03-31 New Buy0.01%$39.51 - $45.38 $ 49.0816%17,794
Bill Nygren 2017-03-31 Sold Out 0.84%$39.51 - $45.38 $ 49.0816%0
David Dreman 2017-03-31 Sold Out 0.02%$39.51 - $45.38 $ 49.0816%0
Dodge & Cox 2016-12-31 Add 15.59%0.33%$37.06 - $42.01 $ 49.0825%68,508,540
Barrow, Hanley, Mewhinney & Strauss 2016-12-31 Reduce -6.20%0.11%$37.06 - $42.01 $ 49.0825%29,377,146
Ken Fisher 2016-12-31 Add 0.39%$37.06 - $42.01 $ 49.0825%12,492,035
HOTCHKIS & WILEY 2016-12-31 Reduce -5.83%0.11%$37.06 - $42.01 $ 49.0825%11,338,645
Charles Brandes 2016-12-31 Reduce -4.78%0.1%$37.06 - $42.01 $ 49.0825%3,387,715
NWQ Managers 2016-12-31 Add 44.15%0.08%$37.06 - $42.01 $ 49.0825%483,670
John Paulson 2016-12-31 Reduce -39.33%0.07%$37.06 - $42.01 $ 49.0825%253,000
Joel Greenblatt 2016-12-31 Add 0.47%$37.06 - $42.01 $ 49.0825%33,032
David Dreman 2016-12-31 Reduce -94.90%0.45%$37.06 - $42.01 $ 49.0825%1,030
Dodge & Cox 2016-09-30 Add 7.45%0.15%$37.83 - $42.63 $ 49.0822%59,267,298
Barrow, Hanley, Mewhinney & Strauss 2016-09-30 Add 11.37%0.19%$37.83 - $42.63 $ 49.0822%31,320,327
Ken Fisher 2016-09-30 Reduce -8.76%0.1%$37.83 - $42.63 $ 49.0822%12,443,197
HOTCHKIS & WILEY 2016-09-30 Add 5.33%0.1%$37.83 - $42.63 $ 49.0822%12,041,028
Charles Brandes 2016-09-30 Reduce -1.19%0.03%$37.83 - $42.63 $ 49.0822%3,557,856
Bill Nygren 2016-09-30 Reduce -42.05%0.67%$37.83 - $42.63 $ 49.0822%3,170,000
John Paulson 2016-09-30 Add 5.44%0.01%$37.83 - $42.63 $ 49.0822%417,000
NWQ Managers 2016-09-30 New Buy0.19%$37.83 - $42.63 $ 49.0822%335,521
Joel Greenblatt 2016-09-30 Reduce -7.57%$37.83 - $42.63 $ 49.0822%32,879
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:XPAR:BOI, XPAR:VIRP, XPAR:VETO, XPAR:AB, XPAR:NANO » details
Traded in other countries:SAN.France, SNW.Germany, SANF.Italy, SNYN.Mexico, SAN.Switzerland, 0O59.UK, SNYNF.USA,
Headquarter Location:France
Sanofi SA is healthcare company which is engaged in the research, development, manufacture and marketing of therapeutic solutions. It business activities include operations of specialty care, Established Prescription Products and vaccines operations.

Sanofi develops and markets drugs with a concentration in oncology, cardiovascular disease, diabetes, and vaccines. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing just over 10% of total sales. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent most of the remainder of sales.

Guru Investment Theses on Sanofi SA

First Eagle Investments Comments on Sanofi - Oct 24, 2016

Sanofi (NYSE:SNY) is a French pharmaceutical company that experienced softness in its diabetes business in the United States. The company’s US patent for Lantus, its primary insulin drug, expired in 2015, and competition from less expensive biosimilars weighted on Sano-fi’s share price. At the same time, Sanofi’s vaccines business and the specialty care areas its acquired in the purchase of Genzyme did well during the quarter.



From First Eagle Global Value Fund third-quarter 2016 commentary.



Check out First Eagle Investment latest stock trades

Top Ranked Articles about Sanofi SA

Sanofi and NIH researchers develop "three-in-one" antibodies as a potential breakthrough intervention for HIV/AIDS
Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
Patient-Driven Dose Titration with Sanofi's Toujeo Improved Blood Glucose Control Without Increasing Hypoglycemia Risk in Real-Life Clinical Practice
Daily Blood Glucose Measures in Phase 3 Clinical Trials Demonstrated Better Stability with Sanofi's Toujeo® vs. Insulin Glargine 100 Units/mL
Sanofi's Soliqua® 100/33 Provided Earlier Blood Sugar Control than Insulin Glargine 100 Units/mL
Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma
Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma
Sanofi Receives Tentative FDA Approval of Admelog® (insulin lispro injection) 100 Units/mL
Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017
Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER

Ratios

vs
industry
vs
history
PE Ratio 11.36
SNY's PE Ratio is ranked higher than
60% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.93 vs. SNY: 11.36 )
Ranked among companies with meaningful PE Ratio only.
SNY' s PE Ratio Range Over the Past 10 Years
Min: 9.75  Med: 20.14 Max: 32.04
Current: 11.36
9.75
32.04
Forward PE Ratio 13.89
SNY's Forward PE Ratio is ranked higher than
73% of the 67 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.90 vs. SNY: 13.89 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 22.25
SNY's PE Ratio without NRI is ranked higher than
57% of the 554 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.21 vs. SNY: 22.25 )
Ranked among companies with meaningful PE Ratio without NRI only.
SNY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.04  Med: 20.14 Max: 32.67
Current: 22.25
10.04
32.67
Price-to-Owner-Earnings 15.92
SNY's Price-to-Owner-Earnings is ranked higher than
78% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.90 vs. SNY: 15.92 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SNY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.31  Med: 13.38 Max: 21.33
Current: 15.92
7.31
21.33
PB Ratio 1.81
SNY's PB Ratio is ranked higher than
68% of the 751 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. SNY: 1.81 )
Ranked among companies with meaningful PB Ratio only.
SNY' s PB Ratio Range Over the Past 10 Years
Min: 1.16  Med: 1.65 Max: 2.33
Current: 1.81
1.16
2.33
PS Ratio 3.09
SNY's PS Ratio is ranked lower than
52% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. SNY: 3.09 )
Ranked among companies with meaningful PS Ratio only.
SNY' s PS Ratio Range Over the Past 10 Years
Min: 1.76  Med: 2.67 Max: 4.12
Current: 3.09
1.76
4.12
Price-to-Free-Cash-Flow 18.57
SNY's Price-to-Free-Cash-Flow is ranked higher than
64% of the 208 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.89 vs. SNY: 18.57 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SNY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.49  Med: 14.97 Max: 21.14
Current: 18.57
7.49
21.14
Price-to-Operating-Cash-Flow 13.61
SNY's Price-to-Operating-Cash-Flow is ranked higher than
68% of the 277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.02 vs. SNY: 13.61 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SNY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.08  Med: 10.73 Max: 17.15
Current: 13.61
6.08
17.15
EV-to-EBIT 16.93
SNY's EV-to-EBIT is ranked higher than
52% of the 559 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.11 vs. SNY: 16.93 )
Ranked among companies with meaningful EV-to-EBIT only.
SNY' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.1  Med: 16.7 Max: 24.6
Current: 16.93
9.1
24.6
EV-to-EBITDA 11.96
SNY's EV-to-EBITDA is ranked higher than
66% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.50 vs. SNY: 11.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
SNY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.1  Med: 8.6 Max: 15
Current: 11.96
5.1
15
EV-to-Revenue 3.10
SNY's EV-to-Revenue is ranked lower than
52% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.22 vs. SNY: 3.10 )
Ranked among companies with meaningful EV-to-Revenue only.
SNY' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.9  Med: 2.9 Max: 4.4
Current: 3.1
1.9
4.4
Shiller PE Ratio 21.33
SNY's Shiller PE Ratio is ranked higher than
78% of the 198 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.37 vs. SNY: 21.33 )
Ranked among companies with meaningful Shiller PE Ratio only.
SNY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.64  Med: 19.97 Max: 27.21
Current: 21.33
14.64
27.21
Current Ratio 1.59
SNY's Current Ratio is ranked lower than
68% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. SNY: 1.59 )
Ranked among companies with meaningful Current Ratio only.
SNY' s Current Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.6 Max: 2.71
Current: 1.59
0.79
2.71
Quick Ratio 0.64
SNY's Quick Ratio is ranked lower than
68% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.82 vs. SNY: 0.64 )
Ranked among companies with meaningful Quick Ratio only.
SNY' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.14 Max: 2.41
Current: 0.64
0.59
2.41
Days Inventory 321.75
SNY's Days Inventory is ranked lower than
87% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. SNY: 321.75 )
Ranked among companies with meaningful Days Inventory only.
SNY' s Days Inventory Range Over the Past 10 Years
Min: 178.09  Med: 195.24 Max: 321.75
Current: 321.75
178.09
321.75
Days Sales Outstanding 73.51
SNY's Days Sales Outstanding is ranked lower than
52% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. SNY: 73.51 )
Ranked among companies with meaningful Days Sales Outstanding only.
SNY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.29  Med: 76.54 Max: 83.73
Current: 73.51
61.29
83.73
Days Payable 434.72
SNY's Days Payable is ranked higher than
83% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.96 vs. SNY: 434.72 )
Ranked among companies with meaningful Days Payable only.
SNY' s Days Payable Range Over the Past 10 Years
Min: 104.92  Med: 125.26 Max: 434.72
Current: 434.72
104.92
434.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.33
SNY's Dividend Yield % is ranked higher than
86% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. SNY: 3.33 )
Ranked among companies with meaningful Dividend Yield % only.
SNY' s Dividend Yield % Range Over the Past 10 Years
Min: 2.46  Med: 3.74 Max: 5.24
Current: 3.33
2.46
5.24
Dividend Payout Ratio 0.79
SNY's Dividend Payout Ratio is ranked lower than
88% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. SNY: 0.79 )
Ranked among companies with meaningful Dividend Payout Ratio only.
SNY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.46  Med: 0.72 Max: 1.02
Current: 0.79
0.46
1.02
3-Year Dividend Growth Rate 1.90
SNY's 3-Year Dividend Growth Rate is ranked lower than
64% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. SNY: 1.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
SNY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -15.6  Med: 7.8 Max: 37.9
Current: 1.9
-15.6
37.9
Forward Dividend Yield % 3.34
SNY's Forward Dividend Yield % is ranked higher than
84% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. SNY: 3.34 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.86
SNY's 5-Year Yield-on-Cost % is ranked higher than
77% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. SNY: 3.86 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
SNY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.85  Med: 4.34 Max: 6.07
Current: 3.86
2.85
6.07
3-Year Average Share Buyback Ratio 0.80
SNY's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 473 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. SNY: 0.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SNY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.5  Med: -0.1 Max: 2.2
Current: 0.8
-24.5
2.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 36.90
SNY's Price-to-Tangible-Book is ranked lower than
92% of the 690 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.51 vs. SNY: 36.90 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SNY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.98  Med: 14.99 Max: 2791.33
Current: 36.9
4.98
2791.33
Price-to-Intrinsic-Value-Projected-FCF 1.01
SNY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
84% of the 328 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. SNY: 1.01 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SNY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 1.21 Max: 2.47
Current: 1.01
0
2.47
Price-to-Median-PS-Value 1.15
SNY's Price-to-Median-PS-Value is ranked lower than
56% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. SNY: 1.15 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SNY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 1.11 Max: 8.74
Current: 1.15
0
8.74
Price-to-Graham-Number 6.04
SNY's Price-to-Graham-Number is ranked lower than
82% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. SNY: 6.04 )
Ranked among companies with meaningful Price-to-Graham-Number only.
SNY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.92  Med: 3.79 Max: 41.46
Current: 6.04
1.92
41.46
Earnings Yield (Greenblatt) % 5.90
SNY's Earnings Yield (Greenblatt) % is ranked higher than
67% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. SNY: 5.90 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SNY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.1  Med: 6 Max: 11
Current: 5.9
4.1
11
Forward Rate of Return (Yacktman) % 1.82
SNY's Forward Rate of Return (Yacktman) % is ranked lower than
67% of the 380 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.46 vs. SNY: 1.82 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
SNY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.7  Med: 10.85 Max: 24
Current: 1.82
0.7
24

More Statistics

Revenue (TTM) (Mil) $39,518.94
EPS (TTM) $ 4.00
Beta0.72
Short Percentage of Float0.00%
52-Week Range $36.81 - 50.24
Shares Outstanding (Mil)2,503.85 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 44,211 45,638 47,804
EPS ($) 3.39 3.56 4.09
EPS without NRI ($) 3.39 3.56 4.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
1.94%
Dividends per Share ($) 1.82 1.88 2.07
» More Articles for SNY

Headlines

Articles On GuruFocus.com
Sanofi and NIH researchers develop "three-in-one" antibodies as a potential breakthrough interventio Sep 20 2017 
Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Mod Sep 16 2017 
Patient-Driven Dose Titration with Sanofi's Toujeo Improved Blood Glucose Control Without Increasing Sep 14 2017 
Daily Blood Glucose Measures in Phase 3 Clinical Trials Demonstrated Better Stability with Sanofi's Sep 13 2017 
Sanofi's Soliqua® 100/33 Provided Earlier Blood Sugar Control than Insulin Glargine 100 Units/mL Sep 12 2017 
Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Sep 11 2017 
Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designatio Sep 08 2017 
Sanofi Receives Tentative FDA Approval of Admelog® (insulin lispro injection) 100 Units/mL Sep 01 2017 
Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ES Aug 25 2017 
Sanofi Raises FY 2017 Business EPS Guidance to Broadly Stable at CER Jul 31 2017 

More From Other Websites
Alnylam Rockets On Strong Rare-Disease Drug Data; Ionis Tanks Sep 20 2017
Alnylam Notches a Game-Changing RNAi Win Sep 20 2017
Sanofi and NIH researchers develop "three-in-one" antibodies as a potential breakthrough... Sep 20 2017
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Soars on Drug Breakthrough Sep 20 2017
UPDATE: Alnylam shares jump 24% on positive results from late-stage trial of hATTR amyloidosis... Sep 20 2017
Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in... Sep 20 2017
Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in... Sep 20 2017
Why Exelixis Wouldn't Be a Warren Buffett Stock Sep 20 2017
5 Top Marijuana Stocks For 2017 Sep 18 2017
Could Mylan See a Rise in Net Profit Margins in 2017? Sep 18 2017
Kevzara May Emerge as a Prominent Rheumatoid Arthritis Drug in 2017 Sep 18 2017
Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With... Sep 16 2017
Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With... Sep 16 2017
Label Expansion in Asthma Indication May Boost Dupixent’s Sales Sep 15 2017
Dupixent Expected to Become a Leading Therapy for Atopic Dermatitis Sep 15 2017
Why Lexicon Pharmaceuticals Is Down 11% Today Sep 14 2017
Patient-Driven Dose Titration with Sanofi's Toujeo Improved Blood Glucose Control Without Increasing... Sep 14 2017
Sanofi indicates dupilumab could be used to treat nasal polyps Sep 12 2017
Sanofi's Soliqua® 100/33 Provided Earlier Blood Sugar Control than Insulin Glargine 100 Units/mL Sep 12 2017
5 Things Regeneron's CEO Said as the Biotech Stock Sank Sep 12 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}